FPF
EVFM

FNY Partners Fund’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

FNY Partners Fund’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-260
Closed -$37K – 1282
2017
Q1 		$37K Buy
+260
New +$33.7K ﹤0.01% 804

Other funds holding EVFM

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Partners Fund's EVFM Position: Q2 2017 in Review

FNY Partners Fund sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2017, closing a stake of 260 shares — an estimated $37K sold.

FNY Partners Fund first reported a position in EVFM in Q1 2017 and held it in 1 quarter. The position peaked at $37K in Q1 2017. 15 funds tracked by Wall St. Rank hold EVFM as of Q2 2017.

  • FNY Partners Fund reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 260 Evofem Biosciences, Inc. Common Stock shares in Q2 2017, an estimated $37K.
  • FNY Partners Fund first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Evofem Biosciences, Inc. Common Stock position peaked at $37K in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.